Thoughts on transatlantic regulatory cooperation in pharmaceuticals after: #TTIPleaks

Research output: Contribution to journalArticle

Abstract

The leak of confidential documents on 2 May 2016 by GreenpeaceNetherlands allows some preliminary conclusions on both the scope and success of the negotiations so far. As regards the pharmaceuticalmarket, the current state of affairs combines the promise of steps forward with the prospect of concerning standstills. This short opinion follows key points emerging from the leaked documents n.9 (“RegulatoryCooperation”) andn.16 (“TacticalState ofPlay”) that are directly relevant to the pharmaceutical market. The themes that will be briefly discussed are, first, the regulatory cooperation mechanisms emerging fromdoc. n.9 in comparison to current cooperation processes in pharmaceutical regulation. The leaked papers suggest positive and commendable (yet far from conclusive) developments towards amore transparent and regulated framework for cooperation, while perpetuating concerns regarding fundamental policy choices and prevalence ofmercantile imperatives over competing public interests.
Original languageEnglish
Pages (from-to)280-284
Number of pages5
JournalEuropean Journal of Risk Regulation
Volume7
Issue number2
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

pharmaceutical
Drug products
pharmaceutical market
public interest
regulation

Cite this

@article{fac853804f2a463db453c84b7ee8f33e,
title = "Thoughts on transatlantic regulatory cooperation in pharmaceuticals after: #TTIPleaks",
abstract = "The leak of confidential documents on 2 May 2016 by GreenpeaceNetherlands allows some preliminary conclusions on both the scope and success of the negotiations so far. As regards the pharmaceuticalmarket, the current state of affairs combines the promise of steps forward with the prospect of concerning standstills. This short opinion follows key points emerging from the leaked documents n.9 (“RegulatoryCooperation”) andn.16 (“TacticalState ofPlay”) that are directly relevant to the pharmaceutical market. The themes that will be briefly discussed are, first, the regulatory cooperation mechanisms emerging fromdoc. n.9 in comparison to current cooperation processes in pharmaceutical regulation. The leaked papers suggest positive and commendable (yet far from conclusive) developments towards amore transparent and regulated framework for cooperation, while perpetuating concerns regarding fundamental policy choices and prevalence ofmercantile imperatives over competing public interests.",
author = "Marco Rizzi",
year = "2016",
doi = "10.1017/S1867299X00005687",
language = "English",
volume = "7",
pages = "280--284",
journal = "European Journal of Risk Regulation",
issn = "1867-299X",
publisher = "Lexxion",
number = "2",

}

Thoughts on transatlantic regulatory cooperation in pharmaceuticals after: #TTIPleaks. / Rizzi, Marco.

In: European Journal of Risk Regulation, Vol. 7, No. 2, 2016, p. 280-284.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Thoughts on transatlantic regulatory cooperation in pharmaceuticals after: #TTIPleaks

AU - Rizzi, Marco

PY - 2016

Y1 - 2016

N2 - The leak of confidential documents on 2 May 2016 by GreenpeaceNetherlands allows some preliminary conclusions on both the scope and success of the negotiations so far. As regards the pharmaceuticalmarket, the current state of affairs combines the promise of steps forward with the prospect of concerning standstills. This short opinion follows key points emerging from the leaked documents n.9 (“RegulatoryCooperation”) andn.16 (“TacticalState ofPlay”) that are directly relevant to the pharmaceutical market. The themes that will be briefly discussed are, first, the regulatory cooperation mechanisms emerging fromdoc. n.9 in comparison to current cooperation processes in pharmaceutical regulation. The leaked papers suggest positive and commendable (yet far from conclusive) developments towards amore transparent and regulated framework for cooperation, while perpetuating concerns regarding fundamental policy choices and prevalence ofmercantile imperatives over competing public interests.

AB - The leak of confidential documents on 2 May 2016 by GreenpeaceNetherlands allows some preliminary conclusions on both the scope and success of the negotiations so far. As regards the pharmaceuticalmarket, the current state of affairs combines the promise of steps forward with the prospect of concerning standstills. This short opinion follows key points emerging from the leaked documents n.9 (“RegulatoryCooperation”) andn.16 (“TacticalState ofPlay”) that are directly relevant to the pharmaceutical market. The themes that will be briefly discussed are, first, the regulatory cooperation mechanisms emerging fromdoc. n.9 in comparison to current cooperation processes in pharmaceutical regulation. The leaked papers suggest positive and commendable (yet far from conclusive) developments towards amore transparent and regulated framework for cooperation, while perpetuating concerns regarding fundamental policy choices and prevalence ofmercantile imperatives over competing public interests.

U2 - 10.1017/S1867299X00005687

DO - 10.1017/S1867299X00005687

M3 - Article

VL - 7

SP - 280

EP - 284

JO - European Journal of Risk Regulation

JF - European Journal of Risk Regulation

SN - 1867-299X

IS - 2

ER -